CoViPa – Virological and immunological determinants of COVID-19 pathogenesis - lessons to get prepared for future pandemics:
The research network CoViPa, funded by the Helmholtz Association, is dedicated to addressing major unresolved questions surrounding pandemic viruses. Through interdisciplinary collaboration, the network aims to generate critical insights into pandemic viruses and those that have pandemic potential, in order to better prepare society for future pandemics.
Our Key Focus Areas:
🔬 The replication mechanisms of SARS-CoV-2 and novel therapeutic concepts to combat infections by this and other viruses with pandemic potential
💉Studies of immune responses induced by SARS-CoV-2 infection and vaccination against this and other emerging viruses
🌍 Future Pandemic Preparedness: Strategies and technologies to respond effectively to future threats
Confirmed Keynote Speakers
We are excited to welcome world-renowned experts:
- Gülsah Gabriel (Leibniz Institute of Virology Hamburg; University of Veterinary Medicine Hannover, Germany)
- Marion Koopmans (Erasmus University Medical Center Rotterdam, The Netherlands)
- Florian Krammer (Medical University of Vienna, Austria; Icahn School of Medicine at Mount Sinai, USA)
- Leif Erik Sander (Charité-Universitätsmedizin Berlin, Berlin Institute of Health, Germany)
- Andreas Wack (Francis Crick Institute London, UK)
We are looking forward to your registration !
The call for abstracts is now open !
The CoViPa Research Network
POSTER
You're welcome to print our conference poster and help us share the conference invitation in your institute:
PanPrep2025 CoViPa Poster
VENUE
German Cancer Research Center (DKFZ)
Heidelberg, Germany
Directions can be found under the "How to find us" section in the upper left menu.
Registration fee for regular participants
60 €
Organizer:
German Cancer Research Center (DKFZ)
Hosts:
Prof. Dr. Dr. h. c. Ralf Bartenschlager
German Cancer Research Center, Heidelberg
Prof. Dr. Ulrike Protzer
Helmholtz Munich, Munich
Funded by:
Initiative and Networking Fund
